← Back to Investors

Abingworth

One of the oldest life sciences venture capital firms in the world, with a transatlantic presence investing across therapeutics, diagnostics, and life science tools. Over 50 years of experience in life sciences investing.

Location
London, UK / Boston, USA
Founded
1973
AUM
$3B+
Investment Range
$5M - $50M
Portfolio Companies
34
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

Abingworth invests globally in life science companies developing breakthrough therapeutic, diagnostic, and medtech innovations. With over 50 years of experience, they focus on companies with strong science and potential for significant clinical and commercial impact. Their transatlantic team brings deep sector expertise and operational experience.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Joe Anderson, PhD - Managing Partner
  • Kurt von Emster - Managing Partner
  • Tim Haines - Managing Partner
  • Stephen Bunting - Partner

Other Key Team Members

  • Genghis Lloyd-Harris - Partner

Focus Areas

  • Therapeutics
  • Oncology
  • Rare Diseases
  • Diagnostics
  • Medical Devices
  • Life Science Tools
  • Gene & Cell Therapy

Notable Exits

  • Horizon Therapeutics - Acquired (2023, by Amgen for $27.8B)
  • Epizyme - Acquired (2022, by Ipsen for $1.45B)
  • Ablynx - Acquired (2018, by Sanofi for €3.9B)
  • Kite Pharma - Acquired (2017, by Gilead for $11.9B)

Sources

Portfolio Companies

NameLocationFoundedCategories
Adicet BioRedwood City, California, USA-
cell-therapybiotech+3
AdvanCell---
Antares Therapeutics--
biotechtherapeutics
Ascend Advanced TherapiesRockville, Maryland, USA-
biotechgene-therapy+3
Attena--
biotechtherapeutics
AvillionLondon, United Kingdom2013
pharmaceuticaldrug-development+3
Cytospire Therapeutics--
biotechtherapeutics
Entact Bio--
biotechtherapeutics
ExicureChicago, Illinois, USA2012
biotechgenetic-medicine+2
GenSight BiologicsParis, France2012
gene-therapybiotech+2
GlycomineSan Carlos, California, USA2012
rare-diseasetherapeutics+2
HilleVaxCambridge, Massachusetts, USA2019
biotechvaccines+2
Jasper TherapeuticsRedwood City, California, USA2019
biotechstem-cell-transplant+2
Launch TherapeuticsSan Diego, California, USA2020
biotechtherapeutics+2
Median TechnologiesSophia Antipolis, France2002
healthcare-technologymedical-imaging+3
Nido BiosciencesBoston, Massachusetts, USA2019
biotechmicrobiome+3
Noveome BiotherapeuticsPittsburgh, Pennsylvania, USA2006
biotechregenerative-medicine+2
NuCanaEdinburgh, United Kingdom2008
oncologycancer-therapeutics+2
OnKure TherapeuticsBoulder, Colorado, USA2019
biotechoncology+2
OptheaMelbourne, Australia2007
biotechophthalmology+2
OrbusNeich MedicalHong Kong, China1996
medical-devicescardiovascular+1
Pathaly--
healthcarebiotech+1
Phathom PharmaceuticalsFlorham Park, New Jersey, USA2018
pharmaceuticalsgastroenterology+1
Q32 BioCambridge, Massachusetts, USA2018
biotechautoimmune+2
Solve TherapeuticsBoston, Massachusetts, USA2020
biotechtherapeutics+2
SoteriaUnited Kingdom-
biotechtherapeutics+1
Timberlyne TherapeuticsBoston, Massachusetts, USA2021
biotechtherapeutics+2
Tizona TherapeuticsSouth San Francisco, California, USA2014
biotechimmunotherapy+2
Trishula TherapeuticsUnited Kingdom-
biotechtherapeutics+1
Venatorx PharmaceuticalsMalvern, Pennsylvania, USA2010
biotechpharmaceuticals+2
WugenSt. Louis, Missouri, USA2018
biotechcell-therapy+2
Iambic TherapeuticsSan Diego, California, USA2019
therapeuticsdrug-discovery+2
Spruce BiosciencesDaly City, California, USA2016
therapeuticsbiotech+3
Myricx BioLondon, United Kingdom2019
therapeuticsbiotech+3